Drugs Made In America Acquisition Corp
DMAA10.440USD
-0.010-0.10%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
349.92MMarktkapitalisierung
95.17KGV TTM
mehr Informationen über Drugs Made In America Acquisition Corp Unternehmen
Drugs Made In America Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenues.
Drugs Made In America Acquisition Corp Informationen
BörsenkürzelDMAA
Name des UnternehmensDrugs Made In America Acquisition Corp
IPO-datumJan 28, 2025
CEOStockwell (Lynn)
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeJan 28
Addresse1 East Broward Boulevard
StadtFT LAUDERDALE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl33301
Telefon19548703099
Website
BörsenkürzelDMAA
IPO-datumJan 28, 2025
CEOStockwell (Lynn)
Führungskräfte von Drugs Made In America Acquisition Corp
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Catherine Do
Dr. Catherine Do
Independent Director Nominee
Independent Director Nominee
100.00K
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Catherine Do
Dr. Catherine Do
Independent Director Nominee
Independent Director Nominee
100.00K
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Mon, Nov 17
Aktualisiert: Mon, Nov 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Drugs Made In America Acquisition LLC
25.57%
Karpus Investment Management
7.60%
First Trust Capital Management L.P.
6.69%
Polar Asset Management Partners Inc.
5.67%
Glazer Capital, LLC
5.44%
Andere
49.03%
Aktionäre
Aktionäre
Anteil
Drugs Made In America Acquisition LLC
25.57%
Karpus Investment Management
7.60%
First Trust Capital Management L.P.
6.69%
Polar Asset Management Partners Inc.
5.67%
Glazer Capital, LLC
5.44%
Andere
49.03%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
30.42%
Corporation
25.57%
Investment Advisor/Hedge Fund
24.61%
Investment Advisor
5.80%
Research Firm
5.62%
Individual Investor
1.19%
Andere
6.79%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
47
22.21M
67.76%
-8.45K
2025Q3
47
22.22M
67.76%
+1.02M
2025Q2
38
21.21M
54.90%
+2.81M
2025Q1
25
18.33M
0.00%
+18.33M
2024Q4
5
4.59M
15.73%
+4.59M
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Drugs Made In America Acquisition LLC
8.57M
25.57%
+4.38M
+104.63%
Feb 25, 2025
Karpus Investment Management
2.55M
7.6%
-196.44K
-7.16%
Sep 30, 2025
First Trust Capital Management L.P.
2.24M
6.69%
--
--
Sep 30, 2025
Polar Asset Management Partners Inc.
1.90M
5.67%
--
--
Sep 30, 2025
Glazer Capital, LLC
1.82M
5.44%
-158.00
-0.01%
Sep 30, 2025
Westchester Capital Management, LLC
1.67M
4.98%
--
--
Sep 30, 2025
Hudson Bay Capital Management LP
1.55M
4.62%
-250.00K
-13.89%
Sep 30, 2025
Wolverine Asset Management, LLC
1.25M
3.73%
+227.22K
+22.24%
Sep 30, 2025
Mizuho Securities USA, LLC.
1.10M
3.28%
+180.66K
+19.64%
Sep 30, 2025
Aristeia Capital, L.L.C.
881.72K
2.63%
--
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
CrossingBridge Pre-Merger SPAC ETF
0%
CrossingBridge Pre-Merger SPAC ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
